SAFETY DATA SHEET

Ertugliflozin (< 2%) / Sitagliptin Formulation

Section 1: Identification

Product name : Ertugliflozin (< 2%) / Sitagliptin Formulation

Manufacturer or supplier’s details

Company : MSD
Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand
Telephone : +1-908-740-4000
Emergency telephone number : +1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Section 2: Hazard identification

GHS Classification

Skin corrosion/irritation : Category 2
Serious eye damage/eye irritation : Category 2A

GHS label elements

Hazard pictograms :

Signal word : Warning

Hazard statements :
H315 Causes skin irritation.
H319 Causes serious eye irritation.

Precautionary statements :

Prevention:
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ eye protection/ face protection.

Response:
P302 + P352 IF ON SKIN: Wash with plenty of water.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Other hazards which do not result in classification
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>Chemical name: Sitagliptin, CAS-No.: 654671-77-9, Concentration: &gt;= 30 - &lt; 60</td>
</tr>
<tr>
<td>Cellulose</td>
<td>Chemical name: Cellulose, CAS-No.: 9004-34-6, Concentration: &gt;= 30 - &lt; 60</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>Chemical name: Ertugliflozin, CAS-No.: 1210344-83-4, Concentration: &gt;= 1 - &lt; 3</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>Chemical name: Magnesium stearate, CAS-No.: 557-04-0, Concentration: &lt; 10</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes skin irritation. Causes serious eye irritation.

Protection of first-aides: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media: Water spray, Alcohol-resistant foam, Carbon dioxide (CO2), Dry chemical

Unsuitable extinguishing: None known.
Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Metal oxides
Oxides of phosphorus

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not get on skin or clothing.
Do not breath dust.
Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>654671-77-9</td>
<td>TWA</td>
<td>0.5 mg/m3 (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>WES-TWA</td>
<td>10 mg/m3</td>
<td>NZ OEL</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1210344-83-4</td>
<td>TWA</td>
<td>10 µg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>WES-TWA</td>
<td>10 mg/m3</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m3</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m3</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

Engineering measures: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection:

Material: Chemical-resistant gloves

Remarks: Consider double gloving.

Eye protection:

Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection:

Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

Appearance: powder

Colour: No data available

Odour: No data available

Odour Threshold: No data available

pH: No data available

Melting point/freezing point: No data available

Initial boiling point and boiling range: No data available

Flash point: Not applicable

Evaporation rate: Not applicable

Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids): No data available
Section 10: Stability and reactivity

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes: Inhalation, Skin contact, Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:
Sitagliptin:
Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg
LD50 (Mouse): 3,000 mg/kg

Cellulose:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Ertugliflozin:
Acute oral toxicity : LD50 (Rat): 500 mg/kg
Acute inhalation toxicity : Remarks: No data available
Acute dermal toxicity : Remarks: No data available

Magnesium stearate:
Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation
Causes skin irritation.

Components:
Sitagliptin:
Species : Rabbit
Method : Draize Test
Result : No skin irritation
SAFETY DATA SHEET

Ertugliflozin (< 2%) / Sitagliptin Formulation

Ertugliflozin:
Result: Corrosive

Magnesium stearate:
Species: Rabbit
Result: No skin irritation
Remarks: Based on data from similar materials

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:
Sitagliptin:
Species: Rabbit
Result: Irritating to eyes.
Method: Draize Test

Ertugliflozin:
Result: Severe irritation

Magnesium stearate:
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:
Sitagliptin:
Test Type: Local lymph node assay (LLNA)
Species: Mouse
Method: OECD Test Guideline 429
Result: Not a skin sensitizer.

Ertugliflozin:
Test Type: Local lymph node assay (LLNA)
Result: Not a skin sensitizer.

Magnesium stearate:
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
**SAFETY DATA SHEET**

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

**Result**: negative

**Remarks**: Based on data from similar materials

**Chronic toxicity**

**Germ cell mutagenicity**

Not classified based on available information.

**Components:**

**Sitagliptin:**

**Genotoxicity in vitro**: Test Type: Ames test

Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: rat hepatocytes
Result: negative

**Genotoxicity in vivo**: Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

**Cellulose:**

**Genotoxicity in vitro**: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

**Genotoxicity in vivo**: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

**Ertugliflozin:**

**Genotoxicity in vitro**: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

**Genotoxicity in vivo**: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Rat
Result: negative
Magnesium stearate:

*Genotoxicity in vitro*
- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative
  - Remarks: Based on data from similar materials

  Test Type: Chromosome aberration test in vitro
  - Method: OECD Test Guideline 473
  - Result: negative
  - Remarks: Based on data from similar materials

  Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
  - Remarks: Based on data from similar materials

**Carcinogenicity**
Not classified based on available information.

**Components:**

**Sitagliptin:**
- Species: Mouse
- Application Route: Oral
- Exposure time: 2 Years
- Result: negative

- Species: Rat
  - Application Route: oral (drinking water)
  - Exposure time: 2 Years
  - Result: positive
  - Target Organs: Liver
  - Remarks: Significant toxicity observed in testing

**Cellulose:**
- Species: Rat
  - Application Route: Ingestion
  - Exposure time: 72 weeks
  - Result: negative

**Ertugliflozin:**
- Species: Mouse
  - Application Route: Oral
  - Exposure time: 2 Years
  - Result: negative

- Species: Rat
  - Application Route: Oral
  - Exposure time: 2 Years
  - Result: negative

**Carcinogenicity - Assessment**
- Weight of evidence does not support classification as a carcinogen
Reproductive toxicity
Not classified based on available information.

Components:

Sitagliptin:
Effects on fertility
: Test Type: Fertility/early embryonic development
  Species: Rat
  Application Route: Oral
  Fertility: NOAEL Parent: 1,000 mg/kg body weight
  Result: Animal testing did not show any effects on fertility.

Effects on foetal development
: Test Type: Embryo-foetal development
  Species: Rat
  Application Route: Oral
  Teratogenicity: LOAEL: 250 mg/kg body weight
  Result: Embryotoxic effects and adverse effects on the offspring were detected, No teratogenic effects

Cellulose:
Effects on fertility
: Test Type: One-generation reproduction toxicity study
  Species: Rat
  Application Route: Ingestion
  Result: negative

Ertugliflozin:
Effects on fertility
: Test Type: Fertility/early embryonic development
  Species: Rat
  Application Route: Oral
  Fertility: NOAEL: 250 mg/kg body weight
  Remarks: Maternal toxicity observed.
  No significant adverse effects were reported

  Test Type: Fertility/early embryonic development
  Species: Rabbit
  Application Route: Oral
  Fertility: NOAEL: 200 mg/kg body weight
  Remarks: No significant adverse effects were reported

Effects on foetal development
: Test Type: Embryo-foetal development
  Species: Rat
SAFETY DATA SHEET

Ertugliflozin (< 2%) / Sitagliptin Formulation

Application Route: Oral
Developmental Toxicity: NOAEL: 50 mg/kg body weight
Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 250 mg/kg body weight
Remarks: No significant adverse effects were reported

Magnesium stearate:
Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Components:

Ertugliflozin:
Exposure routes : Oral
Target Organs : Kidney, Stomach, Prostate
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Sitagliptin:
Species : Mouse
NOAEL : 500 mg/kg
LOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : > 2 yr
Target Organs : Kidney

Species : Rat
NOAEL : 500 mg/kg
LOAEL : 1,000 mg/kg
<table>
<thead>
<tr>
<th>Application Route</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>14 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver, Kidney, Heart, Teeth</td>
</tr>
<tr>
<td>Species</td>
<td>Dog</td>
</tr>
<tr>
<td>NOAEL</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>53 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Loss of balance</td>
</tr>
<tr>
<td>Remarks</td>
<td>The mechanism or mode of action may not be relevant in humans.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>53 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Loss of balance</td>
</tr>
<tr>
<td>Remarks</td>
<td>The mechanism or mode of action may not be relevant in humans.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>2 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 Weeks</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Cellulose:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>&gt;= 9,000 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
</tbody>
</table>

**Ertugliflozin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>500 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>250 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>25 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>180 d</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney, Bone, Stomach</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Ertugliflozin (< 2%) / Sitagliptin Formulation

Species: Rat
LOAEL: 25 mg/kg
Exposure time: 90 d
Target Organs: Kidney, Gastrointestinal tract, Prostate

Species: Dog
NOAEL: 150 mg/kg
Application Route: Oral
Exposure time: 270 d
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 28 d
Target Organs: Bone
Remarks: No significant adverse effects were reported

Magnesium stearate:
Species: Rat
NOAEL: > 100 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Remarks: Based on data from similar materials

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Sitagliptin:
Inhalation: Symptoms: upper respiratory tract infection, pharyngitis, Headache
Ingestion: Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhoea

Ertugliflozin:
Ingestion: Symptoms: The most common side effects are: Headache, constipation, Diarrhoea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection
Section 12: Ecological information

**Ecotoxicity**

**Components:**

**Sitagliptin:**
- **Toxicity to fish:** LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 203
- **Toxicity to daphnia and other aquatic invertebrates:** EC50 (Daphnia magna (Water flea)): 60 mg/l
  Exposure time: 48 h
  Method: OECD Test Guideline 202
- **Toxicity to algae/aquatic plants:** EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 201
  NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 201
- **Toxicity to fish (Chronic toxicity):** NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l
  Exposure time: 33 d
  Method: OECD Test Guideline 210
- **Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):** NOEC (Daphnia magna (Water flea)): 9.8 mg/l
  Exposure time: 21 d
  Method: OECD Test Guideline 211
- **Toxicity to microorganisms:** EC50: > 150 mg/l
  Exposure time: 3 h
  Method: OECD Test Guideline 209
  Test Type: Respiration inhibition
  NOEC: 150 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition

**Cellulose:**
- **Toxicity to fish:** LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
  Exposure time: 48 h
  Remarks: Based on data from similar materials

**Ertugliflozin:**
- **Toxicity to algae/aquatic plants:** EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
  NOEC (Pseudokirchneriella subcapitata (green algae)): 50
### Toxicity to fish (Chronic toxicity)
- **NOEC (Pimephales promelas (fathead minnow)):** 1 mg/l
- **Exposure time:** 32 d
- **Method:** OECD Test Guideline 210
- **Remarks:** No toxicity at the limit of solubility

### Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)
- **NOEC (Daphnia magna (Water flea)):** 2.14 mg/l
- **Exposure time:** 21 d
- **Method:** OECD Test Guideline 211
- **Remarks:** No toxicity at the limit of solubility

### Toxicity to microorganisms
- **EC50:** > 1,000 mg/l
- **Exposure time:** 3 h
- **Test Type:** Respiration inhibition
- **Method:** OECD Test Guideline 209

### Magnesium stearate:
- **LC50 (Leuciscus idus (Golden orfe)):** > 100 mg/l
- **Exposure time:** 48 h
- **Method:** DIN 38412
- **Remarks:** Based on data from similar materials

### Toxicity to daphnia and other aquatic invertebrates
- **EL50 (Daphnia magna (Water flea)):** > 1 mg/l
- **Exposure time:** 47 h
- **Test substance:** Water Accommodated Fraction
- **Remarks:** Based on data from similar materials
  - No toxicity at the limit of solubility

### Toxicity to algae/aquatic plants
- **EL50 (Pseudokirchneriella subcapitata (green algae)):** > 1 mg/l
- **Exposure time:** 72 h
- **Test substance:** Water Accommodated Fraction
- **Method:** OECD Test Guideline 201
- **Remarks:** Based on data from similar materials
  - No toxicity at the limit of solubility
  - **NOELR (Pseudokirchneriella subcapitata (green algae)):** > 1 mg/l
  - **Exposure time:** 72 h
  - **Test substance:** Water Accommodated Fraction
  - **Method:** OECD Test Guideline 201
  - **Remarks:** Based on data from similar materials

### Toxicity to microorganisms
- **EC10 (Pseudomonas putida):** > 100 mg/l
- **Exposure time:** 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

**Persistence and degradability**

**Components:**

**Sitagliptin:**
- Biodegradability: Result: not rapidly degradable
  - Biodegradation: 39.7 %
  - Exposure time: 28 d
  - Method: OECD Test Guideline 314
- Stability in water: Hydrolysis: 50 % (401 d)
  - Method: OECD Test Guideline 111

**Cellulose:**
- Biodegradability: Result: Readily biodegradable.

**Ertugliflozin:**
- Biodegradability: Result: Not readily biodegradable.
  - Biodegradation: 40.8 %
  - Exposure time: 28 d

**Magnesium stearate:**
- Biodegradability: Result: Not biodegradable
  - Remarks: Based on data from similar materials

**Bioaccumulative potential**

**Components:**

**Sitagliptin:**
- Partition coefficient: n-octanol/water: log Pow: -0.03

**Ertugliflozin:**
- Partition coefficient: n-octanol/water: log Pow: 2.47

**Magnesium stearate:**
- Partition coefficient: n-octanol/water: log Pow: > 4

**Mobility in soil**

**Components:**

**Sitagliptin:**
- Distribution among environmental compartments: log Koc: 4.37

**Ertugliflozin:**
Distribution among environmental compartments: log Koc: 2.88

Other adverse effects: No data available

Section 13: Disposal considerations

Disposal methods
- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UN/RTDG
- UN number: Not applicable
- Proper shipping name: Not applicable
- Class: Not applicable
- Subsidiary risk: Not applicable
- Packing group: Not applicable
- Labels: Not applicable

IATA-DGR
- UN/ID No.: Not applicable
- Proper shipping name: Not applicable
- Class: Not applicable
- Subsidiary risk: Not applicable
- Packing group: Not applicable
- Labels: Not applicable
- Packing instruction (cargo aircraft): Not applicable
- Packing instruction (passenger aircraft): Not applicable

IMDG-Code
- UN number: Not applicable
- Proper shipping name: Not applicable
- Class: Not applicable
- Subsidiary risk: Not applicable
- Packing group: Not applicable
- Labels: Not applicable
- EmS Code: Not applicable
- Marine pollutant: Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

NZS 5433
- UN number: Not applicable
- Proper shipping name: Not applicable
SAFETY DATA SHEET

Ertugliflozin (< 2%) / Sitagliptin Formulation

Class: Not applicable
Subsidiary risk: Not applicable
Packing group: Not applicable
Labels: Not applicable
Hazchem Code: Not applicable

Special precautions for user
Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number
HSR100425 Pharmaceutical Active Ingredients Group Standard 2017

HSW Controls
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS: not determined
DSL: not determined
IECSC: not determined

Section 16: Other information

Further information

Date format: dd.mm.yyyy

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
NZ OEL: New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA: 8-hour, time-weighted average
NZ OEL / WES-TWA: Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with...
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.